UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Lavender oil preparation Silexan is effective in generalized anxiety disorder – a randomized, double-blind comparison to placebo and paroxetine

The international journal of neuropsychopharmacology, 2014-06, Vol.17 (6), p.859-869

2014

Volltextzugriff (PDF)

What happens with schizophrenia patients after their discharge from hospital? Results on outcome and treatment from a “real-world” 2-year follow-up trial

European archives of psychiatry and clinical neuroscience, 2020-09, Vol.270 (6), p.661-671

2020

Volltextzugriff (PDF)

Defining and predicting functional outcome in schizophrenia and schizophrenia spectrum disorders

Schizophrenia research, 2009-09, Vol.113 (2), p.210-217

2009

Volltextzugriff (PDF)

Akathisia and suicidal ideation in first-episode schizophrenia

Journal of clinical psychopharmacology, 2012-10, Vol.32 (5), p.694-698

2012

Volltextzugriff (PDF)

Evaluating Depressive Symptoms in Schizophrenia: A Psychometric Comparison of the Calgary Depression Scale for Schizophrenia and the Hamilton Depression Rating Scale

Psychopathology, 2012-01, Vol.45 (5), p.276-285

2012

Volltextzugriff (PDF)

Psychiatrie

Reprint 2013., 2013

Volltextzugriff (PDF)

Efficacy and safety of silexan, a new, orally administered lavender oil preparation, in subthreshold anxiety disorder – evidence from clinical trials

Wiener medizinische Wochenschrift, 2010-12, Vol.160 (21-22), p.547-556

2010

Volltextzugriff (PDF)

Hypericum extract WS® 5570 for depression - An overview

International journal of psychiatry in clinical practice, 2013-11, Vol.17 (S1), p.1-7

Gastpar, Markus

2013

Volltextzugriff (PDF)

The efficacy of the dopamine D2/D3 antagonist tiapride in maintaining abstinence: a randomized, double-blind, placebo-controlled trial in 299 alcohol-dependent patients

The international journal of neuropsychopharmacology, 2007-10, Vol.10 (5), p.653-660

2007

Volltextzugriff (PDF)

The effect of perazine on the CYP2D6 and CYP2C19 phenotypes as measured by the dextromethorphan and mephenytoin tests in psychiatric patients

Basic & clinical pharmacology & toxicology, 2020-05, Vol.126 (5), p.444-447

2020

Volltextzugriff (PDF)

Silexan, an orally administered Lavandula oil preparation, is effective in the treatment of 'subsyndromal' anxiety disorder: a randomized, double-blind, placebo controlled trial

International clinical psychopharmacology, 2010-09, Vol.25 (5), p.277-287

2010

Volltextzugriff (PDF)

Opiate treatment in depression refractory to antidepressants and electroconvulsive therapy

Journal of clinical psychopharmacology, 2008-10, Vol.28 (5), p.593-595

2008

Volltextzugriff (PDF)

Predictors of Relapse in the Year After Hospital Discharge Among Patients With Schizophrenia

Psychiatric services (Washington, D.C.), 2012-01, Vol.63 (1), p.87-90

2012

Volltextzugriff (PDF)

Attention deficit hyperactivity disorder and borderline personality disorder

Progress in neuro-psychopharmacology & biological psychiatry, 2005-07, Vol.29 (6), p.865-877

2005

Volltextzugriff (PDF)

Comparative Efficacy and Safety of a Once-Daily Dosage of Hypericum Extract STW3-VI and Citalopram in Patients with Moderate Depression: A Double-Blind, Randomised, Multicentre, Placebo-Controlled Study

Pharmacopsychiatry, 2006-03, Vol.39 (2), p.66-75

2006

Volltextzugriff (PDF)

What are residual symptoms in schizophrenia spectrum disorder? Clinical description and 1-year persistence within a naturalistic trial

European archives of psychiatry and clinical neuroscience, 2015-03, Vol.265 (2), p.107-116

2015

Volltextzugriff (PDF)

Steady state plasma levels of the enantiomers of trimipramine and of its metabolites in CYP2D6-, CYP2C19- and CYP3A4/5-phenotyped patients

Therapeutic drug monitoring, 2000-04, Vol.22 (2), p.209-214

2000

Volltextzugriff (PDF)

An early improvement threshold to predict response and remission in first-episode schizophrenia

British journal of psychiatry, 2010-06, Vol.196 (6), p.460-466

2010

Volltextzugriff (PDF)

One-year functional outcomes of naturalistically treated patients with schizophrenia

Psychiatry research, 2012-08, Vol.198 (3), p.378-385

2012

Volltextzugriff (PDF)

Feasibility and outcome of substitution treatment of heroin-dependent patients in specialized substitution centers and primary care facilities in Germany: A naturalistic study in 2694 patients

Drug and alcohol dependence, 2008-06, Vol.95 (3), p.245-257

2008

Volltextzugriff (PDF)

The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Substance Use and Related Disorders. Part 2: Opioid dependence

The world journal of biological psychiatry, 2011-04, Vol.12 (3), p.160-187

2011

Volltextzugriff (PDF)

Validity of remission and recovery criteria for schizophrenia and major depression: comparison of the results of two one-year follow-up naturalistic studies

European archives of psychiatry and clinical neuroscience, 2017-06, Vol.267 (4), p.303-313

2017

Volltextzugriff (PDF)

Buprenorphine in the treatment of opioid dependence

European neuropsychopharmacology, 2004-05, Vol.14 (3), p.209-216

2004

Volltextzugriff (PDF)

Predictors of response and remission in the acute treatment of first-episode schizophrenia patients — Is it all about early response?

European neuropsychopharmacology, 2011-05, Vol.21 (5), p.370-378

2011

Volltextzugriff (PDF)

1 – 25 von 100

Suche als RSS-Feed

Aktive Filter

SpracheEnglisch

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(96)
Mit Volltextzugriff
(76)

Publikationsform

Artikel
(94)
Reviews
(4)
Bücher
(2)

Sprache

Japanisch
(9)
Deutsch
(2)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(78)
Science & Technology
(78)
Humans
(73)
Psychiatry
(63)
Female
(60)
Male
(60)
Adult
(56)
Middle Aged
(40)
Biological And Medical Sciences
(39)
Medical Sciences
(38)
Pharmacology & Pharmacy
(27)
Psychology. Psychoanalysis. Psychiatry
(26)
Neurosciences & Neurology
(25)
Psychiatric Status Rating Scales
(25)
Treatment Outcome
(23)
Schizophrenia
(22)
Clinical Neurology
(21)
Psychopathology. Psychiatry
(21)
Follow-Up Studies
(20)
Aged
(19)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Lavender oil preparation Silexan is effective in generalized anxiety disorder – a randomized, double-blind comparison to placebo and paroxetine

What happens with schizophrenia patients after their discharge from hospital? Results on outcome and treatment from a “real-world” 2-year follow-up trial

Defining and predicting functional outcome in schizophrenia and schizophrenia spectrum disorders

Akathisia and suicidal ideation in first-episode schizophrenia

Evaluating Depressive Symptoms in Schizophrenia: A Psychometric Comparison of the Calgary Depression Scale for Schizophrenia and the Hamilton Depression Rating Scale

Psychiatrie

Efficacy and safety of silexan, a new, orally administered lavender oil preparation, in subthreshold anxiety disorder – evidence from clinical trials

Hypericum extract WS® 5570 for depression - An overview

The efficacy of the dopamine D2/D3 antagonist tiapride in maintaining abstinence: a randomized, double-blind, placebo-controlled trial in 299 alcohol-dependent patients

The effect of perazine on the CYP2D6 and CYP2C19 phenotypes as measured by the dextromethorphan and mephenytoin tests in psychiatric patients

Silexan, an orally administered Lavandula oil preparation, is effective in the treatment of 'subsyndromal' anxiety disorder: a randomized, double-blind, placebo controlled trial

Opiate treatment in depression refractory to antidepressants and electroconvulsive therapy

Predictors of Relapse in the Year After Hospital Discharge Among Patients With Schizophrenia

Attention deficit hyperactivity disorder and borderline personality disorder

Remission in schizophrenia — What are we measuring? Comparing the consensus remission criteria to a CGI-based definition of remission and to remission in major depression

Comparative Efficacy and Safety of a Once-Daily Dosage of Hypericum Extract STW3-VI and Citalopram in Patients with Moderate Depression: A Double-Blind, Randomised, Multicentre, Placebo-Controlled Study

What are residual symptoms in schizophrenia spectrum disorder? Clinical description and 1-year persistence within a naturalistic trial

Steady state plasma levels of the enantiomers of trimipramine and of its metabolites in CYP2D6-, CYP2C19- and CYP3A4/5-phenotyped patients

An early improvement threshold to predict response and remission in first-episode schizophrenia

One-year functional outcomes of naturalistically treated patients with schizophrenia

Feasibility and outcome of substitution treatment of heroin-dependent patients in specialized substitution centers and primary care facilities in Germany: A naturalistic study in 2694 patients

The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Substance Use and Related Disorders. Part 2: Opioid dependence

Validity of remission and recovery criteria for schizophrenia and major depression: comparison of the results of two one-year follow-up naturalistic studies

Buprenorphine in the treatment of opioid dependence

Predictors of response and remission in the acute treatment of first-episode schizophrenia patients — Is it all about early response?

Aktive Filter

Suchergebnisse filtern